LEADER 03658nam  22006975  450 
001 9910253872503321
005 20230810184908.0
010   $a3-319-24223-7
024 7 $a10.1007/978-3-319-24223-1
035   $a(CKB)3710000000539285
035   $a(EBL)4199788
035   $a(SSID)ssj0001596877
035   $a(PQKBManifestationID)16297710
035   $a(PQKBTitleCode)TC0001596877
035   $a(PQKBWorkID)14886337
035   $a(PQKB)10711732
035   $a(DE-He213)978-3-319-24223-1
035   $a(MiAaPQ)EBC4199788
035   $a(PPN)19088536X
035   $a(EXLCZ)993710000000539285
100   $a20151214d2016      u|         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aLung Cancer and Personalized Medicine $eCurrent Knowledge and Therapies /$fedited by Aamir Ahmad, Shirish Gadgeel
205   $a1st ed. 2016.
210  1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2016.
215   $a1 online resource (236 p.)
225 1 $aAdvances in Experimental Medicine and Biology,$x2214-8019 ;$v893
300   $aDescription based upon print version of record.
311   $a3-319-24221-0 
327   $a1 Lung Cancer Statistics -- 2 Epidemiology of Lung Cancer -- 3 Lung Cancer In Never Smokers -- 4 Immune Therapy -- 5 Anti-angiogenesis in personalized therapy of lung cancer -- 6 Target therapy in Lung Cancer -- 7 Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors and Therapeutic Approaches: an update -- 8 KRAS-Mutant Lung Cancers in the Era of Targeted Therapy -- 9 Anaplastic Lymphoma Kinase (ALK) Signaling in Lung Cancer -- 10 Chemotherapy Resistance in Lung Cancer -- 11 Current state of metal-based drugs for the efficient therapy of lung cancers and lung metastases.
330   $aThis, the first of two volumes on personalized medicine in lung cancer, touches on the core issues related to the understanding of lung cancer?statistics and epidemiology of lung cancer?along with the incidence of lung cancer in non-smokers. A major focus of this volume is the state of current therapies against lung cancer?immune, targeted therapies against EGFR TKIs, KRAS, ALK, angiogenesis; the associated challenges, especially resistance mechanisms; and recent progress in targeted drug development based on metal chemistry. Chapters are written by some of the leading experts in the field, who provide a better understanding of lung cancer, the factors that make it lethal, and current research focused on developing personalized treatment plans. With a unique mix of topics, this volume summarizes the current state-of-knowledge on lung cancer and the available therapies.
410  0$aAdvances in Experimental Medicine and Biology,$x2214-8019 ;$v893
606   $aCancer
606   $aMedicine$xResearch
606   $aBiology$xResearch
606   $aInternal medicine
606   $aOncology
606   $aCancer Biology
606   $aBiomedical Research
606   $aInternal Medicine
606   $aOncology
615  0$aCancer.
615  0$aMedicine$xResearch.
615  0$aBiology$xResearch.
615  0$aInternal medicine.
615  0$aOncology.
615 14$aCancer Biology.
615 24$aBiomedical Research.
615 24$aInternal Medicine.
615 24$aOncology.
676   $a610
702   $aAhmad$b Aamir$4edt$4http://id.loc.gov/vocabulary/relators/edt
702   $aGadgeel$b Shirish$4edt$4http://id.loc.gov/vocabulary/relators/edt
906   $aBOOK
912   $a9910253872503321
996   $aLung Cancer and Personalized Medicine$92527563
997   $aUNINA